Navigation Links
Medical schools partner to tackle barriers to minority participation in cancer clinical trials
Date:3/25/2010

The University of Minnesota Medical School today announced the details of a $3.8 million grant by the National Institutes of Health's National Center on Minority Health and Health Disparities (NCMHD) for research focused on minority recruitment and retention in cancer clinical trials. Although much is known about cancer incidence rates in minority populations, little research exists to understand behavior and social environmentthe barriers and biases that limit participation and access to clinical trials. The Enhancing Minority Participation in Clinical Trials (EMPaCT) program aims to address these social issues.

This grant provides resources to explore the social issues that limit minority participation and access to cancer clinical trials. According to the Centers for Disease Control and Prevention, racial and ethnic minorities suffer more from cancer than the U.S. population as a whole, developing certain types of cancer more often with a greater chance of premature death due to late-stage detection.

Speaking to grant participants at an event on Capitol Hill in Washington, D.C., John Ruffin, Ph.D., director of the NCMHD said, "While minorities make up one-third of the U.S. population, few participate in clinical trials for various reasons including cultural or religious factors, lack of awareness, and a historical mistrust of the medical system. This research will start to identify and break down these racial and ethnic communications barriers, help to rebuild the community's trust, increase the participation and retention of racial/ethnic minorities in clinical trials, and will serve as a model that could be implemented at other cancer centers and hospitals nationwide."

To reach numerous African American/Black, Asian, Pacific Islander, Hispanic, and American Indian populations, the EMPaCT program has created a consortium of five U.S. regions with identified lead institutions in those regions. They include: John Hopkins Universit
'/>"/>

Contact: Laura Stroup
lstroup@umn.edu
612-624-9912
University of Minnesota
Source:Eurekalert

1

GOOD

Page: 1 2 3

Related medicine news :

1. Recorders.com Offers Free Dragon Medical 10.1 Upgrades
2. Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange
3. FDA Issues Guidance to Help Streamline Medical Device Clinical Trials
4. Summit Medical Group hosts “Go Red Day” to Raise Awareness of Heart Disease and Stroke
5. LocumTenens.com Sponsors Medical Brigades to Honduras
6. Striking Down Medical Liability Reforms Another Blow to Illinois Poor Lawsuit Climate
7. Operation Smile Expands Its Medical Efforts to Help Earthquake Victims in Haiti
8. Statement From IHA President Maryjane A. Wurth on Illinois Supreme Court Medical Liability Ruling
9. Emergo Group Acquires UK-based Mediqol Ltd.; Greatly Expands Medical Device Consulting Presence in Europe
10. Summit Medical Group Physician Named "Nurses Choice: Top Doctor"
11. Grubb & Ellis Healthcare REIT II Enters Agreement to Acquire Parkway Medical Center near Cleveland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... these findings in the current online edition of ... study could open up new possibilities of early ... tackle diseases before the patient,s nervous system is ... of genetic diseases of the cerebellum and other ... limited control of their muscles. They also suffer ...
(Date:5/22/2013)... baby to finish the last ounce in their bottle might ... soon burn off, a bad habit remains. , Brigham Young ... clinical obesity at 24 months of age strongly traces back ... two, it puts you on a trajectory where you are ... as an adult," said Forste. "That,s a big concern." , ...
(Date:5/22/2013)... May 22, 2013 College and ... access to Adapt Courseware’s new Introduction to ... adaptive framework that responds based on each student’s ... the provider of comprehensive adaptive online curriculum resources ... to develop introductory level general education offerings, enabling ...
(Date:5/22/2013)... 22, 2013 Officials with Alliance Commercial ... cicada services are now in full effect due to ... cicada cycle emerges. , “The cicada emerges in ... they will emerge, so we’re now offering services to ... protected during the invasion,” said R. Brett Madden, Esq., ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 According to ... an autoimmune disorder effecting up to 3 million people ... damage to the small intestine and mal-absorption of nutrients(2). ... as diarrhea, constipation, weight loss and vitamin deficiency, people ... While there are many gluten-free foods that celiac sufferers ...
Breaking Medicine News(10 mins):Health News:A pan-European study: Signs of motor disorders can appear years before disease manifestation 2Health News:A pan-European study: Signs of motor disorders can appear years before disease manifestation 3Health News:Overeating learned in infancy, study suggests 2Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 2Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 3Health News:Alliance Commercial Pest Control, Inc. Now Offering Cicada Protection Services 2Health News:During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula 2Health News:During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula 3
... troubles ,the day after, and protect liver from damage, experts ... a hangover, drink lots of water, get plenty of rest ... study shows that the amino acids and minerals in asparagus ... toxins in alcohol. , Researchers at the Institute of Medical ...
... a technique widely used in studying the human brain. ... signals are generated at brain cell level. This information ... from the Academy of Finland,s Neuroscience Research Programme (NEURO) ... play a key role in the generation of fMRI ...
... and the University of Pittsburgh Medical Center will be ... conjunction with the G20 Pittsburgh Summit Sept. 24-25. These ... how and why the "eds and meds" sector of ... region,s success. The Eds-Meds program will begin at ...
... , RUTHERFORD, N.J., Aug. 28 As ... to soar, and sales and profits are being diverted ... commitment to keep their Vectra(R) products, and the health ... professionals. Through their Bloodhound(R) Technology, a unique track-and-trace barcode ...
... MUMBAI, India, Aug. 28 Sun Pharmaceutical Industries Ltd. (Reuters: ... announced that on August 27, 2009, Sun filed a new ... Antitrust Division of the U.S. Department of Justice to restart ... Tender Offer by Alkaloida Chemical Company Exclusive Group Ltd. (Alkaloida), ...
... someday aid in understanding ADD and more , FRIDAY, Aug. ... in a crowd, it appears that your "mind,s eye" acts ... you until you find the right person. , Researchers from ... monkeys as they searched for a specific tilted, colored bar ...
Cached Medicine News:Health News:Asparagus May Ease Hangover 2Health News:New research findings pave the way to more accurate interpretation of brain imaging data 2Health News:Summit VetPharm Helps Veterinarians Protect Against Product Diversion, Counterfeiting and Shrinkage Using Vectra(R) Bloodhound(R) Technology 2Health News:Summit VetPharm Helps Veterinarians Protect Against Product Diversion, Counterfeiting and Shrinkage Using Vectra(R) Bloodhound(R) Technology 3Health News:Sun Pharmaceutical Files HSR Application for Taro Tender Offer 2Health News:Sun Pharmaceutical Files HSR Application for Taro Tender Offer 3Health News:Brain May Use Its 'Mind's Eye' to Control Chaos 2
(Date:5/22/2013)... Mass. and TORONTO , ... ) (OTCBB: GNBT) today announced three presentations demonstrating the ... by its wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ... meeting of the American Society of Clinical Oncology (ASCO) ... from May 31 through June 4, 2013. ...
(Date:5/22/2013)...  Grifols, ein globales Unternehmen der Gesundheitsbranche ... , Spanien, präsentierte die Ergebnisse einer Studie, ... PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den Spiegel des Alpha1-Proteins ... Niveau anhebt, das innerhalb des für gesunde ... eine lebensbedrohliche, genetische Erkrankung, bei der der ...
(Date:5/22/2013)... and TORONTO , May 22, 2013 ... that John Mon , Chief Operating Officer, ... on Thursday, May 30, 2013 in New York ... The Company,s presentation is scheduled to begin at 4:00 ... To access the webcast, go to:   http://wsw.com/webcast/marcum/mfs.v/   ...
Breaking Medicine Technology:Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3
... Trubion,s Proprietary ... Product Candidate, SBI-087 for RA Expands Trubion,s Family of Customized, Differentiated ... Product Candidates, ... has initiated a Phase 1/2,clinical trial of TRU-016, the company,s lead proprietary Small Modular,ImmunoPharmaceutical ...
... Encouraging Response in CF Patients - Results Validate ... March 27 The Cystic Fibrosis Foundation,announced today that ... defect in CF, showed promising results in an ongoing ... mutation of CF. The drug is,being developed by Vertex ...
Cached Medicine Technology:Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 2Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 3Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 4Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 5Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF 2Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF 3
Malaria Pf. Assay Range...
An immunochromatographic test for detection of 4 species of Plasmodium antigen ( P. falciparum , P. vivax , P. malariae , P. ovale ) in whole blood....
192 Test HRP-II Enzyme Immunoassay for the presence of Plasmodium falciparum infection....
Malaria device / strip (3 line, PAN-pLDH, P.f.-HRP2)...
Medicine Products: